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BACKGROUND: This phase I, open-label, first-in-human study determined dose-limiting toxicities (DLTs) and maximum tolerated dose
(MTD) of PD 0332991, an oral cyclin-dependent kinase 4/6 inhibitor with potent anti-proliferative activity in vitro/vivo.
METHODS: A total of 33 patients with retinoblastoma protein-positive advanced solid tumours or non-Hodgkin’s lymphoma refractory
to standard therapy or for which no therapy was available received PD 0332991 once daily (QD) for 14 days followed by 7 days off
treatment (21-day cycles; Schedule 2/1).
RESULTS: Six patients had DLTs (18%; four receiving 200mg QD; two receiving 225mg QD); the MTD was 200mg QD. Treatment-
related, non-haematological adverse events occurred in 29 patients (88%) during cycle 1 and 27 patients (82%) thereafter. Adverse
events were generally mild–moderate. Of 31 evaluable patients, one with testicular cancer achieved a partial response; nine had
stable disease (X10 cycles in three cases). PD 0332991 was slowly absorbed (mean Tmax 4.2h) and eliminated (mean half-life 26.7h).
Volume of distribution was large (mean 3241l) with dose-proportional exposure. Using a maximum effective concentration model,
neutropenia was proportional to exposure.
CONCLUSION: PD 0332991 was generally well tolerated, with DLTs related mainly to myelosuppression. The MTD, 200mg QD, is
recommended for phase II study.
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Progression through the cell cycle, which is fundamental to cell
proliferation, is controlled by the sequential activation of a family
of related cyclin-dependent kinases (CDKs). Cyclin-dependent
kinase 4 and 6 (CDK4/6) are closely related kinases that, together
with their activating subunits, the D-type cyclins, promote cell-
cycle progression from G1 to S phase via phosphorylation of the
retinoblastoma (Rb) protein (Dickson and Schwartz, 2009).
Most tumours circumvent control of G1 to S progression using a
variety of mechanisms. In a minority of tumours (such as Rb and
small-cell lung cancer), control is lost through mutation of the Rb
gene (Friend et al, 1986; Harbour et al, 1988). In the majority of
cases, however, other genetic and epigenetic changes lead to
increases in CDK4/6 activity contributing to tumour cell growth
(Shapiro, 2006). Tumour cell proliferation may therefore be
particularly sensitive to selective inhibition of CDK4/6.
PD 0332991 is an orally administered, highly specific reversible
inhibitor of CDK4/6 (Fry et al, 2004; Toogood et al, 2005). PD
0332991 has a potent anti-proliferative effect in vitro, leading to
cell-cycle arrest at G1, but has no activity against Rb-negative cell
lines (Fry et al, 2004). Similarly, PD 0332991 significantly reduces
tumour growth and leads to tumour regression in several
Rb-positive human xenograft models in vivo, without activity
against Rb-negative tumours (Fry et al, 2004).
Results from the first-in-human phase I study of PD 0332991 on
a schedule of 2 weeks on treatment followed by 1 week off
treatment (Schedule 2/1) are reported here. This 3-week schedule
allows combination with other cancer therapies that are adminis-
tered using a 3-week dosing cycle.
MATERIALS AND METHODS
Study design
This was a phase I, dose-finding, open-label, non-comparative
study of PD 0332991 in patients with Rb-positive solid tumours or
non-Hodgkin’s lymphoma (NHL). As pre-clinical data suggest that
tumours that do not express Rb will not respond to treatment with
PD 0332991, histologically proven Rb tumour expression was an
essential eligibility criterion for patients entering this study. On
the basis of the low frequency of Rb expression in small-cell
lung cancer and Rb (Lee et al, 1987; Yokota et al, 1988; Shimizu
et al, 1994), patients with both tumour types were excluded from
the trial.
The primary objectives of this study were to establish the safety
profile of PD 0332991 given in a 3-week treatment cycle
by identifying dose-limiting toxicities (DLTs), the maximum
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sadministered dose and the maximum tolerated dose (MTD), and to
establish the recommended dose for phase II studies (RP2D).
Secondary objectives included characterisation of single-dose and
steady-state pharmacokinetics (PKs) of oral PD 0332991 and
evaluation of preliminary antitumour activity.
Study population
Eligible patients were men and women aged X18 years with
histologically or cytologically confirmed Rb-positive solid tumours
(except small-cell lung cancer or Rb) or NHL refractory to
standard therapy, or for whom no standard-of-care therapy was
available. Retinoblastoma expression was assayed by immunohis-
tochemistry at a central laboratory using an archival or fresh
tumour biopsy; eligibility required level X1þ staining (i.e., of at
least the minimal intensity considered above background level).
Additional eligibility criteria included Eastern Cooperative Oncol-
ogy Group (ECOG) performance status p2, the ability to swallow
intact PD 0332991 capsules, and adequate organ and haematological
function, including haemoglobin 49.0gdl
 1 without transfusions
(erythropoietin to be discontinued X2 weeks before the first dose
of study medication).
Patients were ineligible, if they met any of the following criteria:
cytotoxic chemotherapy within 3 weeks before first treatment
(8 weeks for mitomycin C or nitrosoureas); hormone therapy,
radioimmunotherapy, immunotherapy or other biological therapy
within 14 days before treatment; QTc interval 4470 msec; and
untreated brain metastases. Patients with brain metastases were
eligible, if they had completed treatment X10 days before starting
study medication, had discontinued corticosteroid treatment for
these metastases for X5 days and were neurologically stable.
The final study protocol and amendments were reviewed and
approved by the Institutional Review Board/Independent Ethics
Committee at each participating site, in accordance with the
International Conference on Harmonization Good Clinical Practice
guidelines and the Declaration of Helsinki. Written informed
consent was obtained from all patients before study participation.
Treatment
Cohorts of patients received escalating doses of PD 0332991 given
daily for 2 weeks, followed by 1 week off treatment (Schedule 2/1).
Treatment cycles were repeated until the occurrence of disease
progression, unacceptable toxicity or withdrawal of consent.
Three to four evaluable patients were initially enrolled per dose-
escalation cohort, and the cohort expanded to six evaluable
patients, if a DLT occurred during the first treatment cycle. If two
DLTs were observed in a single cohort during the first treatment
cycle, dose escalation was stopped, and dose finding was continued
at a lower level. The MTD was defined as the highest dose level for
which the incidence of first-cycle DLT was o2/6. Cohorts
receiving the MTD were expanded to include a minimum of 12
patients. If o33% of patients in the MTD cohort had a DLT, then
the dose taken by this cohort was considered to be the RP2D.
Dose-limiting toxicity was defined as one of the following
adverse events (AEs) occurring during cycle 1: grade 4 haemato-
logical toxicity; grade 3 neutropenia with infection or fever
X38.51C; grade X3 non-haematological treatment-related toxicity,
except toxicities which had not been maximally treated (such as
nausea, vomiting and diarrhoea) or that the patient considered
tolerable (such as skin rash); confirmed grade 3 QTc prolongation
(QTc 4500ms) persisting after correction of other possible causes
such as electrolyte imbalance or hypoxia; or inability to receive the
next dose of PD 0332991 within 1 week (±1 day) of the last dose
because of lack of haematological recovery or prolonged non-
haematological toxicity grade X3. The dose for patients resuming
treatment following a DLT was reduced to the next lower dose level
or by 50%, if the DLT occurred at the starting dose of the trial.
Safety assessments
Safety was assessed at baseline, at regular intervals throughout
the study, and within 1 week following treatment discontinuation
by recording AEs, haematological and biochemical parameters,
and physical status (including ECOG performance status).
Adverse event severity was graded using the National Cancer
Institute Common Terminology Criteria for Adverse Events,
version 3.0 (Trotti et al, 2003). Triplicate electrocardiograms
(ECGs) B2min apart were taken at baseline, 3h post-dose on days
1, 8 and 15 of cycle 1, and on day 15 of subsequent cycles for up to
six cycles.
Tumour response
Tumour measurements derived from computed tomography or
magnetic resonance imaging scans were obtained at baseline, after
every 2 cycles during the study, and at the end of treatment.
Tumour responses were evaluated based on Response Evaluation
Criteria in Solid Tumors, version 1.0 (Therasse et al, 2000).
Pharmacokinetic assessments
Samples for measurement of PK parameters were collected from all
patients pre-dose and at intervals up to 10h post-dose following a
single administration (cycle one, day 1) and after repeated dosing
(cycle 1, day 8). In cycle 1, three additional blood samples for PK
analysis were collected during the 7-day interval without treatment
on days 15, 16 and 17. In addition a sample was collected from
patients in the expanded MTD cohort 24h post-dose on cycle 1,
day 1. Urine PK assessments (0–10h post-dose) were carried
out on cycle 1, day 1 in patients in the expanded cohort. Blood
draws for PK assessment were also obtained at the same time as
ECG testing at the projected time-to-first occurrence of the
maximum observed plasma concentration (Cmax). Individual area
under the concentration–time curve (AUC) values estimated
based on dose and individual apparent clearance (CL/F) was
obtained from population PK modelling. Additional PK para-
meters assessed were the time-to-first occurrence of Cmax (Tmax),
the apparent volume of distribution during the terminal phase (Vz/F),
the terminal elimination half-life (t1/2) and the drug accumulation
ratio (Rac).
Pharmacodynamic assessments
To document the course of changes in absolute neutrophil count
(ANC) and platelets over time during the first two cycles of
treatment, an exploratory analysis of data available from the
weekly safety laboratory tests was carried out. Possible relation-
ships between PD 0332991 exposure and changes in (i) ANC and
(ii) platelets were assessed further by fitting a simple model
(without baseline) to determine the maximum effective concentra-
tion (Emax). Parameters determined were the Emax for ANC or
platelets as a function of PD 0332991 concentration and the EC50
(the estimated plasma concentration resulting in a change from
baseline of 50% in ANC or platelets). Data from all patients
receiving PD 0332991 on Schedule 2/1 were included in the
exploratory and modelling analyses.
Statistical methods
Pharmacokinetics parameters were determined using non-com-
partmental analyses (WinNonLin version 4.1; Pharsight, Mountain
View, CA, USA). Descriptive statistics for PK parameters were
summarised by dosing group, day and cycle.
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sRESULTS
Patient characteristics and disposition
A total of 33 patients were enrolled across four cohorts receiving
the following daily doses of PD 0332991: 100mg (n¼3), 150mg
(n¼4), 200mg (n¼20) and 225mg (n¼6). Patient baseline
characteristics are shown in Table 1. Overall, patients received a
median of two cycles of treatment (range 1–33). The median
relative dose intensity in each cohort was 1.0 (range 0.29–1.04),
with a total cumulative dose of PD 0332991 administered of
12013mgm
 2 (s.d. 16324mgm
 2). Relative dose intensity was
defined as the cumulative dose (mg per week) from treatment start
till the end of the treatment divided by the planned cumulative
dose, where the end of the treatment was the start date of the last
cycle plus the planned cycle duration.
At the time of analysis, treatment was ongoing in three patients,
and the remaining 30 patients had discontinued because of AEs
(n¼2; none was considered to be treatment related), death (n¼1),
refusal of further treatment (n¼1), progressive disease (n¼25) or
other reasons (n¼1).
Determination of MTD
The sequence of dose escalation progressed from 100 to 150mg
once daily (QD), and then to 225mg QD, which was the maximum
administered dose. The dose was then reduced to 200mg QD.
No DLT was observed in the first two cohorts. In the 225-mg QD
cohort, two of six patients experienced DLTs. These included a
patient who experienced grade 4 neutropenia and thrombocyto-
penia, and a patient with grade 3 neutropenia, such that the
initiation of cycle 2 dosing was delayed, thereby constituting a
DLT. The incidence of neutropenia reported as AEs during cycle 1 is
presented in Table 2. Additional key toxicities reported in the
patients in the 225mg per day cohort experiencing DLTs included
grade 1 fatigue and diarrhoea in the patient with neutropenia as the
DLT, and grade 1 diarrhoea and grade 2 anaemia in the patient who
had neutropenia plus thrombocytopenia.
Because of the DLTs at 225mg QD, an intermediate dose of
200mg QD was selected for evaluation. With only one DLT (grade
3 neutropenia/grade 3 thrombocytopenia resulting in cycle 2
delay) among six patients treated at 200mg QD, this dose level was
selected as the MTD and was expanded to include a total of 20
patients for further evaluation of safety, efficacy and biomarkers.
An additional three patients in the expanded cohort experienced
DLTs, comprising grade 3 neutropenia resulting in cycle two delay
(n¼2) and grade 3 neutropenia with grade 3 thrombocytopenia,
also resulting in cycle 2 delay (n¼1). The four DLTs in the 20-
patient expanded cohort were considered acceptable, as the DLT
rate of 20% was well within the pre-specified upper limit of 33%
used to determine the MTD in the initial dose-escalation cohort.
Overall safety
Treatment was generally well tolerated. No patient discontinued
treatment permanently because of treatment-related AEs. Five
patients required dose reductions, including three patients with
haematological AEs associated with DLTs (two patients receiving
250mg QD and one receiving 200mg QD) and two patients with
gastrointestinal AEs (one patient with grade 2 nausea and one
patient with grade 2 vomiting and headache, both receiving 200mg
QD). In addition, treatment was interrupted following treatment-
related AEs in eight patients receiving 200mg QD during cycle 1
and in three patients after cycle 1 (two from the 200-mg QD cohort
and one in the 225-mg QD cohort).
Treatment-related non-haematological AEs were observed in 29
of 33 patients (88%) across all cohorts during cycle one and in 27
of 33 patients (82%) after cycle one. These AEs were generally mild
to moderate in severity, with no treatment-related grade 4 non-
haematological AEs, no serious treatment-related AEs and no
grade 5 treatment-related AEs observed. Treatment-related AEs
occurring in X5% of patients are presented in Table 3. The most
common non-haematological AEs reported during cycle 1 were
fatigue (33%), nausea (30%), diarrhoea (18%), constipation and
rash (each 12%); after cycle 1, the most frequently reported AEs
comprised diarrhoea and fatigue (each 30%), nausea (15%) and
epistaxis (12%). Five grade 3 non-haematological AEs were
reported (n¼1 each), all of which occurred after the first cycle
and comprised fatigue, hyperglycaemia, hyponatremia, nausea and
vomiting.
Haematological toxicity was common (Table 4). Grade 3 or 4
haematological toxicity consisted of lymphopenia (36%), neutro-
penia (24%), leukopenia (21%), thrombocytopenia (9%) and
anaemia seen in a single patient (3%).
Analysis of QT interval changes using Bazett’s and Fridericia’s
corrections showed that Fridericia’s was the more appropriate
correction method based on plots of the QTc vs RR interval (data
not shown). Using Fridericia’s correction, no patients had a
maximum on-treatment value X500-msec or a 430-msec increase
from baseline.
Table 1 Patient baseline characteristics (N¼33)
Parameter
Age in years, median (range) 63 (35–78)
Male/female, n (%) 16/17 (48.5/51.5)
ECOG PS, n (%)
0 17 (51.5)
1 11 (33.3)
2 5 (15.2)
Primary diagnosis, n (%)
Liposarcoma 7 (21.2)
Colon cancer 6 (18.2)
Melanoma 4 (12.1)
Other 16 (48.5)
Previous therapy, n (%)
Any 32 (97.0)
Previous surgery, n (%) 29 (90.6)
Previous radiotherapy, n (%) 14 (43.8)
Previous chemotherapy, n (%) 27 (84.4)
1 regimen 6 (22.2)
2 regimens 5 (18.5)
3 regimens 8 (29.6)
43 regimens
a 8 (29.6)
Hormonal 2 (6.3)
Immunotherapy/biological 5 (15.6)
Abbreviation: ECOG PS¼Eastern Cooperative Oncology Group performance
status.
aPatients who had received 43 previous chemotherapy regimens were
documented as protocol deviations.
Table 2 Incidence of treatment-emergent neutropenia during cycle 1
Neutropenia, NCICTCAE grade (n)
Dose QD Patients, n Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
1 0 0 m g 3 0 0000
1 5 0 m g 4 0 0000
200mg 20 11 0 3 6 0
2 2 5 m g 6 3 0021
Abbreviations: QD¼once daily; NCICTCAE¼National Cancer Institute Common
Terminology Criteria for Adverse Events.
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Of the total 33 patients, 31 completed at least one post-treatment
tumour assessment and were considered evaluable for response.
One patient with testicular cancer had a partial response (PR) with
PD 0332991 administered at 200mg QD on Schedule 2/1. This
patient had non-seminomatous germ cell tumour and had
previously been treated with bleomycin, cisplatin and etoposide
in the adjuvant setting. An additional nine patients (29%)
experienced stable disease (SD) lasting X2 cycles. Stable disease
was observed in the following tumour types: liposarcoma (n¼4),
thyroid (n¼1), melanoma (n¼1), cholangiosarcoma (n¼1) and
angiomyxoma (n¼1). Six of the patients (19%) with SD had SD
lasting X4 cycles, and three patients (10%) had SD for X10 cycles.
Stable disease lasting X10 cycles was observed in two patients with
liposarcoma (one in the 100-mg QD cohort lasting 11 cycles and
one in the 225-mg QD cohort lasting X23 cycles) and one patient
with angiomyxoma in the 200-mg QD cohort lasting 19 cycles. The
course of patients with liposarcoma can be associated with
prolonged SD. However, the patient with liposarcoma,
who remains on study with SD after 23 cycles, is particularly
noteworthy, having progressed previously on a phase II clinical
trial with sorafenib. In addition, this patient continues on
trial without cumulative toxicity. Two patients were on study at
the time of data cutoff: the patient with testicular cancer who
achieved a PR and the patient with liposarcoma and SD lasting
X23 cycles.
Pharmacokinetics
On day 1 of treatment, PD 0332991 was detectable in the plasma of
all patients at the first measured timepoint (i.e., 1h post-dose).
Exposure (AUC(0–10) and Cmax) increased in a broadly dose-
proportional manner over the range of 100–225mg PD 0332991 on
days 1 and 8, although there was some variability particularly at
the 150-mg dose level (Table 5, Supplementary Figures 1A and B).
Overall, values for Cmax and AUC(0–10) showed low to moderate
inter-patient variability after both single- and multiple-dose
administration. Plasma PK parameters showed low to moderate
variability with a generally dose-dependent increase in exposure
over the dose range of 100–225mg based on Cmax and AUC(0–10).
Area under the concentration–time curve was determined only up
to 10h post-dose because of limited availability of data at later
timepoints. Dose-normalised AUC for PD 0332991 after adminis-
tration of 100–225mg QD demonstrated dose proportionality
(Supplementary Figure 1C).
Following repeated daily dosing to steady state (based on
samples taken from the 200-mg QD cohort), PD 0332991 was
absorbed with a median Tmax of 4.2h. The mean PD 0332991 Vz/F
was 3241l, which is significantly greater than that of total body
water (42l), suggesting that PD 0332991 penetrates extensively into
peripheral tissues. The PD 0332991 was eliminated slowly with a
mean t1/2 of 26.7h; the mean CL/F was 88.5l per hour. Following
repeated dosing, PD 0332991 accumulated with a median Rac of
2.4, which is consistent with the t1/2.
Pharmacodynamics
A nadir in both ANC and levels of platelets was observed at the end
of the dosing period in cycle 1 (Supplementary Figure 2), which
was followed by a rebound in levels of both ANC and platelets
during the off-drug period that continued up to day 8 of cycle 2.
Table 4 Haematological toxicity by maximum toxicity grade among
patients whose toxicity worsened relative to baseline across all cohorts and
all cycles (N¼33)
Haematological toxicity Grade 1/2, n (%) Grade 3/4, n (%)
Anaemia 21 (64) 1 (3)
Leukopenia 22 (67) 7 (21)
Neutropenia 14 (42) 8 (24)
Lymphopenia 8 (24) 12 (36)
Thrombocytopenia 19 (58) 3 (9)
Table 3 Treatment-related non-haematological adverse events
a during
and after cycle one occurring in X5% of patients for all cohorts combined
(N¼33)
Cycle 1, n (%) After cycle 1, n (%)
Adverse event All grades Grade 3 All grades Grade 3
Fatigue 11 (33) 0 10 (30) 1 (3)
Nausea 10 (30) 0 5 (15) 1 (3)
Diarrhoea 6 (18) 0 10 (30) 0
Constipation 4 (12) 0 3 (9) 0
Rash 4 (12) 0 2 (6) 0
Vomiting 2 (6) 0 2 (6) 1 (3)
Peripheral oedema 3 (9) 0 2 (6) 0
Dyspnea 3 (9) 0 1 (3) 0
Anorexia 1 (3) 0 3 (9) 0
Pyrexia 1 (3) 0 2 (6) 0
Epistaxis 0 0 4 (12) 0
Flatulence 0 0 3 (9) 0
Mucosal inflammation 0 0 3 (9) 0
Chills 0 0 2 (6) 0
Muscular weakness 0 0 2 (6) 0
Cough 0 0 2 (6) 0
Alopecia 0 0 2 (6) 0
aAdverse events were defined as treatment-related based on having a relationship to
study drug reported as ‘yes’ or ‘unknown’. No treatment-related, grade 4/5 adverse
events were reported.
Table 5 Mean and median plasma pharmacokinetic parameters for PD 0332991 by dose on days 1 and 8
100mg QD 150mg QD 200mg QD 225mg QD
Parameter
Day 1
(n¼3)
Day 8
(n¼3)
Day 1
(n¼4)
Day 8
(n¼3)
Day 1
(n¼20)
Day 8
(n¼8)
Day 1
(n¼6)
Day 8
(n¼6)
Cmax (ngml
 1), mean (%CV) 44 (72) 58 (43) 78 (22) 194 (41) 81 (35) 174 (17) 104 (58) 186 (64)
Tmax (h), median (range) 4.0 (2.0–10.0) 4.0 (4.0–7.0) 6.0 (4.0–10.0) 7.0 (7.0–10.0) 5.7 (1.0–10.2) 4.0 (2.0–7.0) 4.0 (4.0–7.0) 4.5 (1.0–7.0)
AUC(0–10)
a (nghml
 1),
mean (%CV)
333 (NA) 433 (NA) 622 (NA) 1599 (35) 525 (36) 1395 (23) 718 (55) 1491 (64)
Abbreviations: QD¼once daily; Cmax¼maximum observed plasma concentration; CV¼coefficient of variation; Tmax¼time-to-first occurrence of Cmax; AUC(0–10)¼area
under the plasma concentration–time curve from 0 to 10h; NA¼not applicable.
aThe number of patients on day 1 for the 100-mg, 150-mg and 200-mg cohorts was 2, 2 and
19, respectively, and on day 8 for the 100-mg cohort was 2.
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recovered such that baseline levels were exceeded. From day 9 of
cycle 2, ANC and platelet levels declined to the end of the cycle 2
dosing period. Changes from baseline during cycle 1 in levels of
ANC and platelets vs individual AUC for 30 patients were assessed.
For ANC (Figure 1), Emax was estimated to be 88.6% (s.e. 11.2;
12.6% coefficient of variation (CV) with an EC50 of 716nghml
 1
(s.e. 400; 56.9% CV). For platelets (data not shown), Emax was
estimated to be 92.2% (s.e. 16.9; 18.3% CV) and EC50 was estimated
to be 1370nghml
 1 (s.e. 720; 52.9% CV).
DISCUSSION
This paper presents data from the first-in-human, phase I dose-
escalation study of the potent and selective CDK4/6 inhibitor, PD
0332991. Dosing ranged from 100 to 225mg QD for 2 weeks,
followed by 1 week off treatment (Schedule 2/1).
A total of six patients in the overall study population
experienced DLT. Of these, four (one patient in the dose-escalation
cohort and three patients in the expansion cohort) received a dose
of 200mg QD, which was identified as the MTD. Dose-limiting
toxicities consisted exclusively of myelosuppression (neutropenia
with or without thrombocytopenia), leading to a delay in initiation
of cycle 2 dosing. Overall, myelosuppression was common, with
grade 1/2 leukopenia and thrombocytopenia seen in 58–67% of
patients, grade 3/4 leukopenia and neutropenia in B20–25% of
patients, and grade 3/4 lymphopenia in 36% of patients.
Preliminary pharmacodynamic modelling suggested that myelo-
suppression was related to PD 0332991 exposure. Indeed, based on
preclinical data, myelosupression was an expected toxicity and is
consistent with a mechanism of action that targets the cell cycle
(Lin et al, 2009). Of note, the lymphopenic toxicity of the CDK
inhibitor flavopiridol (see below) resulted in this agent being
tested for the treatment of chronic lymphocytic leukaemia, for
which it has demonstrated promising activity.
Treatment-related, non-haematological toxicity was generally
mild to moderate in intensity with only five grade 3 AEs reported
overall and no treatment-related grade 4 toxicity. The most common
non-haematological AEs included fatigue and gastrointestinal
toxicities consisting primarily of nausea, diarrhoea and constipation,
with some patients also experiencing vomiting. Similar AE profiles
have been reported for other CDK inhibitors targeting the G1/S
checkpoint (Thomas et al, 2002; Dittrich et al, 2003; Mahadevan et al,
2008; Shapiro et al, 2008; Tibes et al, 2008).
Pharmacokinetics analyses using a non-compartmental model
suggest that PD 0332991 exposure increases in a dose-proportional
model over the dose range explored in this study, although there
was low to moderate inter-patient variability. Population PK
studies are ongoing. As anticipated from preclinical data, the half-
life of PD 0332991 was relatively long, at 26.7h, resulting in its
accumulation following repeated dosing. Extensive penetration of
peripheral tissue was suggested by the large Vz/F value (3241l).
Further studies are needed to define precisely when steady state is
reached and to characterise the extent of washout in the 1 week off
treatment embedded within each cycle.
An exploratory analysis of ANC and platelet levels during the
first two treatment cycles showed that levels of both neutrophils
and platelets decreased during PD 0332991 treatment, a pharma-
codynamic observation that is consistent with CDK inhibition in
rapidly dividing cell types. The exploratory analysis demonstrated
that the observed nadirs in percentage decreases from baseline
were equivalent in each cycle and, importantly, decreases in cell
numbers were not cumulative. The lack of cumulative effect
indicated a saturable effect of the drug on both ANC and platelets.
Furthermore, a PK/pharmacodynamic relationship was established
between change in ANC and platelets levels vs plasma exposure
using a simple Emax model, with increasing exposures resulting in a
decrease from baseline for both ANC and platelets that was
saturable. During the 1-week off-drug period, the extent of
recovery of neutrophils and platelets was dependent on the cell
type. It is possible that multiple factors (including system-based
(i.e., cell type) and drug-based) underlie in the overall changes
observed following PD 0332991 treatment. More mechanistic
population PK/pharmacodynamic modelling, based on a pre-
viously described semi-mechanistic physiological model developed
to describe the neutropenic effects of cytotoxic agents such as
docetaxel, etoposide, paclitaxel and irinotecan (Friberg et al, 2002),
is currently underway to investigate further the changes in
ANC and platelet levels associated with PD 0332991 treatment. It
is possible that the use of ANC or platelet modelling may have
utility as surrogate pharmacodynamic markers of PD 0332991
activity.
The PD 0332991 showed preliminary evidence of antitumour
activity in this study, with one PR (Vaughn et al, 2009) and B30%
of patients exhibiting disease stabilisation, which in three cases
was prolonged beyond 10 cycles of treatment. The patient numbers
were too small from which to draw conclusions about differences
in response between cohorts or within any individual tumour type.
The one PR shows that, like certain other cytostatic agents such as
tamoxifen, PD 0332991 is capable of both cytostatic and cytotoxic
activity in the clinic, as suggested by results from some preclinical
models (Fry et al, 2004).
Several other CDK inhibitors are in development (Dickson and
Schwartz, 2009), including flavopiridol, which has activity against
CDK4/6. As previously reported, the activity of PD 0332991 in one
of the patients with testicular cancer is striking (Vaughn et al,
2009). Flavopiridol has also been shown to be active in patients
with germ-cell tumours, especially in combination with oxalipla-
tin-based chemotherapy (Rathkopf et al, 2009). Therefore, CDK
inhibitors, particularly those that target CDK4/6, may offer
promise for patients with this particular disease.
In summary, PD 0332991 given on Schedule 2/1 is generally well
tolerated by patients with advanced solid tumours, with the DLT
being myelosuppression. The MTD on this schedule was 200mg
QD, and this dose is recommended for further study in phase II.
Phase II studies of PD 0332991 are ongoing/planned in patients
with multiple myeloma (ClinicalTrials.gov NCT00555906), breast
cancer (ClinicalTrials.gov NCT00721409) and refractory solid
tumours (ClinicalTrials.gov NCT01037790). In addition, CDK4
has been shown to be amplified in patients with liposarcoma,
which may explain the unusual degree of SD observed in this
clinical trial (Singer et al, 2007). In view of this, a phase II study of
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Figure 1 Pharmacodynamic modelling: percentage change in neutrophil
count vs individual AUC during cycle 1. ANC, absolute neutrophil count;
AUC, area under the plasma concentration–time curve.
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sthis agent in CDK4-amplified, Rb-positive liposarcoma is now
underway (ClinicalTrials.gov NCT01209598).
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